详情页 - 四川省肿瘤医院知识库

资源类型：

文章类型：

作者：

Li, Huiping[1] * ; Zhang, Qingyuan[2] ; Li, Wei[3] ; Wang, Shusen[4] ; Liao, Ning[5] ; Shen, Peng[6] ; Shao, Bin[1] ; Zhao, Wenhui[2] ; Sun, Wan[7] ; Yan, Ping[10] ; Wang, Diane[7] ; Li, Vince (Bai)[11] ; Linn, Carlos[11] ; Shi, Haihong[8] ; O'Gorman, Melissa[9] ; Xu, Binghe[12] ;

机构： [1]Peking Univ, Dept Breast Oncol, Key Lab Carcinogenesis & Translat Res, Minist Educ,Canc Hosp & Inst, Beijing, Peoples R China; [2]Harbin Med Univ, Med Dept 3, Canc Hosp, Harbin, Heilongjiang, Peoples R China; [3]Jilin Univ, Hosp 1, Ctr Canc, Changchun, Jilin, Peoples R China; [4]Sun Yat Sen Univ, Dept Med Oncol, Canc Ctr, Guangzhou, Guangdong, Peoples R China; [5]Guangdong Gen Hosp, Dept Breast Surg, Guangzhou, Guangdong, Peoples R China; [6]Zhejiang Univ, Med Oncol, Affiliated Hosp 1, Coll Med, Hangzhou, Zhejiang, Peoples R China; [7]Pfizer Inc, Clin Pharmacol, Global Prod Dev, San Diego, CA USA; [8]Pfizer Inc, Clin Assay Grp, Dept Clin Pharmacol, Groton, CT USA; [9]Pfizer Inc, Pfizer Innovat Hlth, Clin Pharmacol, Pharmacometr, Groton, CT USA; [10]Pfizer China R&D Co Ltd, Clin Stat Global Biometr & Data Management, Shanghai, Peoples R China; [11]Pfizer China R&D Co Ltd, Clin Dev, Dev China Pfizer, Global Prod Dev, Shanghai, Peoples R China; [12]Chinese Acad Med Sci, Dept Med Oncol, Natl Canc Ctr, Canc Hosp, Beijing 100021, Peoples R China

出处：

DOI：

ISSN：

基金：

语种：

被引次数：

WOS：

中科院(CAS)分区：

出版当年[2017]版：

大类 | 1 区

医学

小类 | 1 区肿瘤学

最新[2023]版：

大类 | 1 区

医学

小类 | 1 区肿瘤学

第一作者：

第一作者机构： [1]Peking Univ, Dept Breast Oncol, Key Lab Carcinogenesis & Translat Res, Minist Educ,Canc Hosp & Inst, Beijing, Peoples R China;

推荐引用方式(GB/T 7714)：

APA：

MLA：

Palbociclib plus letrozole as first-line treatment for ER-positive and HER2-negative advanced breast cancer in Chinese women: a phase 1 study

文献详情